Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Long

Toxicologic pathology

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Toxicologic Pathology|September 1, 1996
Perspectives on pathology peer reviewG Long
Toxicologic Pathology|October 10, 2002
Apparent mesonephric duct (rete anlage) origin for cysts and proliferative epithelial lesions in the mouse ovaryGerald G Long
Toxicologic Pathology|February 4, 2010
Commentary on "Evaluation of possible carcinogenic risk to humans based on liver tumors in rodent assays: the two-year bioassay is no longer necessary"Gerald G Long
Toxicologic Pathology|May 16, 2012
Regulatory forum opinion piece: thresholds in toxicologic pathologyGerald G Long, Jerry F Hardisty
Toxicologic Pathology|June 3, 1998
Appropriate parameters to be tested in rodent oncogenicity studiesG G Long, J T Symanowski
Toxicologic Pathology|June 3, 1998
Precision in data acquisition and reporting of organ weights in rats and miceG G Long, J T Symanowski, K Roback
Toxicologic Pathology|December 22, 2007
Variations in animal populations over time and differences in diagnostic thresholds used can impact tumor incidence dataJohn L Vahle, Masahiko Sato, Gerald G Long
Toxicologic Pathology|November 1, 1993
Incidence of spontaneous neoplastic and nonneoplastic lesions in Charles River CD-1 mice varies with breeding originJ A Engelhardt, C L Gries, G G Long
Toxicologic Pathology|November 17, 2009
Alternative mouse models for carcinogenicity assessment: industry use and issues with pathology interpretationGerald G Long, Daniel Morton, Terry Peters, et al.
Toxicologic Pathology|August 25, 2009
Neoplastic and non-neoplastic changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR alpha/gamma agonistGerald G Long, Vincent L Reynolds, L Wayne Dochterman, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Toxicologic Pathology|September 1, 1996
Perspectives on pathology peer reviewG Long
Toxicologic Pathology|October 10, 2002
Apparent mesonephric duct (rete anlage) origin for cysts and proliferative epithelial lesions in the mouse ovaryGerald G Long
Toxicologic Pathology|February 4, 2010
Commentary on "Evaluation of possible carcinogenic risk to humans based on liver tumors in rodent assays: the two-year bioassay is no longer necessary"Gerald G Long
Toxicologic Pathology|May 16, 2012
Regulatory forum opinion piece: thresholds in toxicologic pathologyGerald G Long, Jerry F Hardisty
Toxicologic Pathology|June 3, 1998
Appropriate parameters to be tested in rodent oncogenicity studiesG G Long, J T Symanowski
Toxicologic Pathology|June 3, 1998
Precision in data acquisition and reporting of organ weights in rats and miceG G Long, J T Symanowski, K Roback
Toxicologic Pathology|December 22, 2007
Variations in animal populations over time and differences in diagnostic thresholds used can impact tumor incidence dataJohn L Vahle, Masahiko Sato, Gerald G Long
Toxicologic Pathology|November 1, 1993
Incidence of spontaneous neoplastic and nonneoplastic lesions in Charles River CD-1 mice varies with breeding originJ A Engelhardt, C L Gries, G G Long
Toxicologic Pathology|November 17, 2009
Alternative mouse models for carcinogenicity assessment: industry use and issues with pathology interpretationGerald G Long, Daniel Morton, Terry Peters, et al.
Toxicologic Pathology|August 25, 2009
Neoplastic and non-neoplastic changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR alpha/gamma agonistGerald G Long, Vincent L Reynolds, L Wayne Dochterman, et al.
Pageof 2